The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

Latest from The University of Texas MD Anderson Cancer Center


Dr. Wang on the FDA Approval of Brexucabtagene Autoleucel in MCL

July 24, 2020

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the FDA approval of brexucabtagene autoleucel (Tecartus; formerly KTE-X19) in mantle cell lymphoma (MCL).

Axi-Cel Retreatment Demonstrates Clinical Efficacy in Large B-Cell Lymphoma

June 24, 2020

Findings from an exploratory analysis of the phase 1/2 ZUMA-1 trial demonstrated clinical efficacy in patients with relapsed/refractory large B-cell lymphoma who were retreated with the CAR T-cell therapy axicabtagene ciloleucel.

Cirmtuzumab Plus Ibrutinib Shows Activity and Tolerability in MCL and CLL

June 16, 2020

Hun Ju Lee, MD, discusses the interim results of a study examining cirmtuzumab plus ibrutinib and the next steps with this research in mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma.